Sandoz Gets Biogen Neurological Treatment Patent Tossed
A London court on Friday tossed Biogen MA Inc.'s patent underpinning its method of assessing whether a rare neurological disorder was valid, following a series of challenges from rival Sandoz....To view the full article, register now.
Already a subscriber? Click here to view full article